JP7445689B2 - 脂肪分解促進剤 - Google Patents
脂肪分解促進剤 Download PDFInfo
- Publication number
- JP7445689B2 JP7445689B2 JP2022023320A JP2022023320A JP7445689B2 JP 7445689 B2 JP7445689 B2 JP 7445689B2 JP 2022023320 A JP2022023320 A JP 2022023320A JP 2022023320 A JP2022023320 A JP 2022023320A JP 7445689 B2 JP7445689 B2 JP 7445689B2
- Authority
- JP
- Japan
- Prior art keywords
- gliasperin
- lipolysis
- licorice extract
- licorice
- lipolysis promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004130 lipolysis Effects 0.000 title claims description 56
- 229940069445 licorice extract Drugs 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 14
- 229940010454 licorice Drugs 0.000 claims description 14
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 8
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 8
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 8
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 8
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 8
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 235000013305 food Nutrition 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 240000004670 Glycyrrhiza echinata Species 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 239000003925 fat Substances 0.000 description 13
- 210000001596 intra-abdominal fat Anatomy 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004003 subcutaneous fat Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000002366 lipolytic effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- PDKHNRSRVURSHL-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound O=C1C=2C(O)=C(CC=C(C)C)C(OC)=CC=2OCC1C1=CC=C(O)C=C1O PDKHNRSRVURSHL-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 241001279772 Glycyrrhiza pallidiflora Species 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- -1 troches Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 240000002635 Dendrocalamus asper Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 244000308760 Helichrysum petiolatum Species 0.000 description 1
- 235000013537 Helichrysum petiolatum Nutrition 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- RTRZOHKLISMNRD-UHFFFAOYSA-N isoflavanone Chemical class C1OC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 RTRZOHKLISMNRD-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
[2]上記グリアスペリンBが、甘草抽出物由来である、[1]に記載の脂肪分解促進剤。
[3]上記甘草抽出物が、甘草の含水エタノール抽出物である、[2]に記載の脂肪分解促進剤。
[4]上記含水エタノール中のエタノール濃度が、0.1%(v/v)~99.9%(v/v)である、[3]に記載の脂肪分解促進剤。
[5]上記含水エタノール中のエタノール濃度が、30%(v/v)~70%(v/v)である、[4]に記載の脂肪分解促進剤。
[6]グリアスペリンBの含有量が、0.00001質量%~50質量%である、[1]から[5]のいずれかに記載の脂肪分解促進剤。
本発明の脂肪分解促進剤は、グリアスペリンBを有効成分として含有する。本発明の脂肪分解促進剤は、必須成分であるグリアスペリンBに加えて、本発明の効果を損なわない範囲でその他の成分を含有していてもよい。以下に、本発明の脂肪分解促進剤が含むグリアスペリンB、及びその他の成分、本発明の脂肪分解促進剤の形態等について説明する。
グリアスペリンB(Glyasperin B、以下「GB」ともいう)は、下記式で表される、イソフラバノン誘導体である。3-(2,4-ジヒドロキシフェニル)-5-ヒドロキシ-2,3-ジヒドロ-6-(3-メチル-2-ブテニル)-7-メトキシ-4H-1-ベンゾピラン-4-オン、3-(2,4-ジヒドロキシフェニル)-5-ヒドロキシ-6-(3-メチル-2-ブテニル)-7-メトキシ-3,4-ジヒドロ-2H-1-ベンゾピラン-4-オン、又は3-(2,4-ジヒドロキシフェニル)-5-ヒドロキシ-7-メトキシ-6-(3-メチルブタ-2-エン-1-イル)-3,4-ジヒドロ-2H-1-ベンゾピラン-4-オンとも表される。
本発明の脂肪分解促進剤は、グリアスペリンBに加えて、本発明の効果を損なわない範囲で、担体、賦形剤、溶媒、その他の任意成分を含有してもよい。
カンゾウ抽出物1gあたり10mlの蒸留水を加えて溶解させカンゾウ抽出物水溶液を調製した。この水溶液の容量に対して半量の酢酸エチルを加えて混和し二層に分離した状態とし、そこから酢酸エチル層を回収する操作を3度繰り返した。得られた酢酸エチル層に無水硫酸ナトリウムを加えた後、ろ過をすることで有機画分を得た。有機画分をエバポレーターにて濃縮した後、シリカゲルカラムクロマトグラフにて、ヘキサン:酢酸エチル=1:1(v/v)で溶出した画分を、ODSカラムを用いた高速液体クロマトグラフ(アセトニトリル:水=60:40,45:55(いずれもv/v))により精製を繰り返すことで、化合物(グリアスペリンB)を得た。ここで得られたグリアスペリンB(GB)を以下のマウス前駆脂肪細胞3T3-L1を使用した試験において被験物質として用いた。
13C-NMR(重アセトン)ppm:17.6, 21.4, 25.7, 47.2, 56.2, 71.0, 91.3, 103.5, 103.7, 107.6, 109.7, 113.5, 123.3, 131.1,131.5, 156.8, 158.7, 161.1, 162.7, 165.8, 198.7
ESI+-MS m/z:393.13059[M+Na]+(計算値、C21H22O6Na:393.13086)
カラム;TSKgel ODS-100V 5μm(東ソー)4.6mm(内径)×150mm(長さ)
カラム温度;40℃、移動相;アセトニトリル:水=45:55(v/v)
流速;1ml/min
検出波長;290nm
GBの保持時間;33.2分
マウス前駆脂肪細胞3T3-L1を、分化誘導培地(0.5mM Isobutyl-methylxanthine、1μM Dexamethasone、1μg/mL Insulin in 10%FBS/DMEM)にて2日間培養した後、1μg/mLのInsulinを含有する10%FBS/DMEM培地に交換して7日間培養した。被験物質(カンゾウ抽出物及びGB)は分化誘導開始から9日目において添加し、その後19時間培養した。カンゾウ抽出物としては、試験1で用いたカンゾウ抽出物を用い(最終濃度100μg/mL、200μg/mL、300μg/mL)、GBとしては、試験1で調製したGBを用いた(最終濃度13.5ng/mL、27ng/mL、40ng/mL)。各群3例として試験を行った。細胞中に蓄積している中性脂肪が分解して培地中に放出されるグリセロールを、ラボアッセイ(TM)トリグリセライド(富士フィルム和光純薬)にて定量した。結果を図1に示す。グリセロール量は、平均値±標準偏差で示した。図1中の各符号は以下を示す。** p<0.01 vs.無処置(Student’s t検定)。
被験者(59歳の男性1名)は、試験1で用いたカンゾウ抽出物を一日あたり200mg、100日間摂取した。被験者には記録用紙を渡し、タニタの体組成計にて測定した体重、BMI及び内臓脂肪レベルをカンゾウ抽出物の摂取開始前(0日目)、摂取30日目、摂取45日目、摂取72日目、摂取83日目、摂取92日目及び最終摂取日翌日(101日目)に記録させた。摂取開始前からの体重、BMI及び内臓脂肪レベルの変化量を図2に示す。
Claims (8)
- グリアスペリンBを有効成分として含有する、脂肪分解促進剤。
- 上記グリアスペリンBが、甘草抽出物由来である、請求項1に記載の脂肪分解促進剤。
- 上記甘草抽出物が、甘草の含水エタノール抽出物である、請求項2に記載の脂肪分解促進剤。
- 上記含水エタノール中のエタノール濃度が、0.1%(v/v)~99.9%(v/v)である、請求項3に記載の脂肪分解促進剤。
- 上記含水エタノール中のエタノール濃度が、30%(v/v)~70%(v/v)である、請求項4に記載の脂肪分解促進剤。
- グリアスペリンBの含有量が、0.00001質量%~50質量%である、請求項1から5のいずれか1項に記載の脂肪分解促進剤。
- グリアスペリンB量として1日あたり5μg~100μgで投与される、請求項1から6のいずれか1項に記載の脂肪分解促進剤。
- グリチルリチン酸を含有しないか、又はグリチルリチン酸を含有する場合にはグリアスペリンBの含有量をグリチルリチン酸の含有量で除した値が0.001以上である、請求項1から7のいずれか1項に記載の脂肪分解促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022023320A JP7445689B2 (ja) | 2022-02-17 | 2022-02-17 | 脂肪分解促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022023320A JP7445689B2 (ja) | 2022-02-17 | 2022-02-17 | 脂肪分解促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023120103A JP2023120103A (ja) | 2023-08-29 |
JP7445689B2 true JP7445689B2 (ja) | 2024-03-07 |
Family
ID=87778163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022023320A Active JP7445689B2 (ja) | 2022-02-17 | 2022-02-17 | 脂肪分解促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7445689B2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070263A1 (fr) | 2002-02-20 | 2003-08-28 | Kaneka Corporation | Procede de production d'un extrait hydrophobe de glycyrrhiza de haute qualite |
WO2008143182A1 (ja) | 2007-05-17 | 2008-11-27 | Kaneka Corporation | 甘草ポリフェノールを含有する組成物 |
JP2013159579A (ja) | 2012-02-06 | 2013-08-19 | Kao Corp | Ppar活性化剤 |
WO2017094892A1 (ja) | 2015-12-03 | 2017-06-08 | エムジーファーマ株式会社 | 健康肥満維持剤 |
-
2022
- 2022-02-17 JP JP2022023320A patent/JP7445689B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070263A1 (fr) | 2002-02-20 | 2003-08-28 | Kaneka Corporation | Procede de production d'un extrait hydrophobe de glycyrrhiza de haute qualite |
WO2008143182A1 (ja) | 2007-05-17 | 2008-11-27 | Kaneka Corporation | 甘草ポリフェノールを含有する組成物 |
JP2013159579A (ja) | 2012-02-06 | 2013-08-19 | Kao Corp | Ppar活性化剤 |
WO2017094892A1 (ja) | 2015-12-03 | 2017-06-08 | エムジーファーマ株式会社 | 健康肥満維持剤 |
Non-Patent Citations (2)
Title |
---|
J. Nutri.,2003年,vol.133, no.11,pp.3369-3377 |
天然有機化合物討論会講演要旨集,2003年,vol.45, no.50(P-15),pp.293-298 |
Also Published As
Publication number | Publication date |
---|---|
JP2023120103A (ja) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
JP2016199536A (ja) | 筋肉増強およびメタボリックシンドローム改善ならびにqol改善のための組成物 | |
JP2008297209A (ja) | 脂質代謝改善組成物 | |
US20190070129A1 (en) | Composition comprising panduratin or fingerroot (boesenbergia pandurata) extract for treating, preventing, or ameliorating bone loss disease | |
KR101760512B1 (ko) | 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물 | |
JP2011201788A (ja) | 抗炎症剤 | |
JP5403942B2 (ja) | グルタチオン産生促進剤およびグルタチオンの欠乏に起因する疾患の予防・治療剤 | |
JP5027361B2 (ja) | ヒアルロン酸産生促進剤 | |
JP2016160238A (ja) | ナチュラルキラー細胞活性促進剤 | |
JP7445689B2 (ja) | 脂肪分解促進剤 | |
JP2017178805A (ja) | Lps産生抑制剤、及びlps産生抑制用の食品組成物 | |
JP4537024B2 (ja) | 炎症疾患予防・治療剤 | |
KR101732146B1 (ko) | 옥수수수염 및 탱자 복합추출물을 함유하는 항비만용 조성물 | |
KR20150087728A (ko) | 개똥쑥 추출물, 아테미시닌 또는 디히드로아테미시닌을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
JP6456032B2 (ja) | Sirt1活性化剤および当該Sirt1活性化剤の利用 | |
JP4371431B2 (ja) | 抗アレルギー性組成物 | |
JP7274725B2 (ja) | 慢性疲労症候群の治療剤 | |
JP4809611B2 (ja) | 脂肪細胞の脂肪蓄積阻害剤 | |
JP2011032177A (ja) | Kit切断抑制剤 | |
JP2009249331A (ja) | 植物由来の高脂血症の予防または改善剤 | |
JP2011132147A (ja) | 濃縮赤ワインエキスを有効成分とする中性脂肪吸収阻害剤 | |
JP7239135B2 (ja) | α-グルコシダーゼ活性阻害剤および血糖値上昇抑制剤 | |
JP6629036B2 (ja) | 皮膚化粧料および飲食品 | |
KR20130117962A (ko) | 복분자 추출물 또는 이로부터 분리된 에틸아세테이트분획물을 함유하는 뼈 성장촉진효과를 나타내는 식품조성물 | |
JP2021063053A (ja) | 環境汚染物質によるダメージ抑制剤、化粧料及び飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7445689 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |